New Delhi: Drug firm Cipla on Tuesday said it plans to launch fixed-dose combination anti-malarial drug in India in partnership with non-profit organisation, Drugs for Neglected Diseases Initiative (DNDi).The company said it has collaborated with DNDi to launch fixed-dose combination of Artesunate (AS) and Mefloquine (MQ) to treat malaria caused by microorganism `P falciparum`.
Indian jawan`s beheading: Army Chief warns Pak
Exclusive interview with Natwar Singh
Aamir Khan poses naked in `PK` poster
Trilokpuri mishap: E-rickshaw driver arrested